Disease · MONDO_0005072

neuroblastoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. neuroblastoma. Diseases, record MONDO_0005072. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005072

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: neuroblastoma; Open Targets
Open Targets ID: MONDO_0005072; Open Targets
Other names: (neuroblastoma NOS) or (sympathicoblastoma), Central neuroblastoma, NB - Neuroblastoma, Neuroblastoma, NOS, Neuroblastomas, Sympathicoblastoma, [M]Neuroblastoma NOS, [M]Neuroblastoma NOS (morphologic abnormality), neural Crest tumor, malignant, neuroblastoma (Schwannian Stroma-poor), neuroblastoma (morphologic abnormality), neuroblastoma NOS (morphologic abnormality), neuroblastoma, malignant; Open Targets
Disease Ontology: DOID:769; Disease Ontology
MeSH: D009447; MeSH
NCI Thesaurus: C3270; NCI Thesaurus
Orphanet: ORPHA:635; Orphanet
Highest stage of its drugs: Approval, for 5 of its 173 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs173

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MELPHALAN	CHEMBL852	Small molecule	Approval	EMA Human Drugs	34	33	33	Drugs and targets
IOBENGUANE I 131	CHEMBL1615779	Small molecule	Approval	DailyMed	29	27	8	Drugs and targets
DINUTUXIMAB	CHEMBL3137342	Antibody	Approval	DailyMed	28	26	22	Drugs and targets
NAXITAMAB	CHEMBL4297984	Antibody	Approval	DailyMed, FDA and TTD	21	18	18	Drugs and targets
DINUTUXIMAB BETA	CHEMBL5315068	Antibody	Approval	EMA Human Drugs	16	15	15	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	82	82	81	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	56	56	56	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	46	46	46	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 3	ClinicalTrials.gov	42	41	41	Drugs and targets
SARGRAMOSTIM	CHEMBL1201670	Protein	Phase 3	ClinicalTrials.gov	39	39	21	Drugs and targets

1 to 10 of 173

See all 173 drugs

Targets225

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBB	Tubulin	9	Tubulin beta inhibitor; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	9	Tubulin beta inhibitor; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	9	Tubulin beta inhibitor; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	9	Tubulin beta inhibitor; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347733	Drugs and targets
TUBB3	Tubulin	9	Tubulin beta inhibitor; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10381	Drugs and targets
TUBB4A	Tubulin	9	Tubulin beta inhibitor; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10382	Drugs and targets
TUBB4B	Tubulin	9	Tubulin beta inhibitor; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10383	Drugs and targets
TUBB6	Tubulin	9	Tubulin beta inhibitor; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84617	Drugs and targets
TUBB8	Tubulin	9	Tubulin beta inhibitor; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347688	Drugs and targets
TUBA1A	Tubulin	8	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets

1 to 10 of 225

See all 225 targets

Trials298

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 18 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00026312	Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma	Phase 3	1,449	2017-03-29	Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma	ALDESLEUKIN, DINUTUXIMAB, ISOTRETINOIN, SARGRAMOSTIM	Its record names the disease	ClinicalTrials.gov
NCT00567567	Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma	Phase 3	665	2017-06-27	Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma	CARBOPLATIN, CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, MELPHALAN, THIOTEPA, TOPOTECAN HYDROCHLORIDE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00499616	Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma	Phase 3	464	2017-06-27	Neuroblastoma	CARBOPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, ISOTRETINOIN, TOPOTECAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00072358	Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma	Phase 2	291	2022-05-16	Neuroblastoma	ANTI-GD2 MONOCLONAL ANTIBODY 3F8, SARGRAMOSTIM	Its record names the disease	ClinicalTrials.gov
NCT01587703	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers	Phase 1	196	2020-03-16	Carcinoma, Midline	MOLIBRESIB	Its record names the disease	ClinicalTrials.gov
NCT01857934	Therapy for Children With Advanced Stage Neuroblastoma	Phase 2	153	2023-02-24	Neuroblastoma	CYCLOPHOSPHAMIDE, TOPOTECAN	Its record names the disease	ClinicalTrials.gov
NCT01798004	Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma	Phase 1	150	2017-02-09	Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma	BUSULFAN, CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, MELPHALAN, MESNA, TOPOTECAN HYDROCHLORIDE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas	Phase 1/2	140	2023-01-10	Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02124772	Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations	Phase 1/2	139	2021-07-14	Cancer	DABRAFENIB, TRAMETINIB	Its record names the disease	ClinicalTrials.gov
NCT00939770	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Phase 1/2	122	2020-05-05	Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma	CRIZOTINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 298

See all 298 trials

Comparisons in its trials40

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Regimen A vs Regimen B: serious adverse events	10 of 112	785 of 1,328	1,440	NCT00026312	Trial comparisons
Disease Evaluable by I-MIBG Scintigraphy (ABT-751) vs Measurable Disease by CT or MRI Scan (ABT-751): serious adverse events	3 of 44	4 of 47	91	NCT00436852	Trial comparisons
Regimen A (Chemotherapy, Dinutuximab, Sargramostim) vs Regimen B (Eflornithine, Chemotherapy, Dinutuximab): deaths from any cause	13 of 44	19 of 47	91	NCT03794349	Trial comparisons
Regimen A (Chemotherapy, Dinutuximab, Sargramostim) vs Regimen B (Eflornithine, Chemotherapy, Dinutuximab): serious adverse events	3 of 44	20 of 47	91	NCT03794349	Trial comparisons
Arm I (Temozolomide, Irinotecan Hydrochloride, Temsirolimus) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Dinutuximab): deaths from any cause	12 of 18	15 of 51	69	NCT01767194	Trial comparisons
Arm I (Temozolomide, Irinotecan Hydrochloride, Temsirolimus) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Dinutuximab): serious adverse events	5 of 18	18 of 51	69	NCT01767194	Trial comparisons
Disease Eval by Bone Marrow or MIBG (Irinotecan/Temozolomide) vs Disease Measurable by CT or MRI Scan (Irinotecan/Temozolomide): Overall Response - Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)	5 of 27	3 of 28	55	NCT00311584	Trial comparisons
Disease Eval by Bone Marrow or MIBG (Irinotecan/Temozolomide) vs Disease Measurable by CT or MRI Scan (Irinotecan/Temozolomide): serious adverse events	0 of 27	1 of 28	55	NCT00311584	Trial comparisons
UTC ch14.18 vs NCI ch14.18: serious adverse events	17 of 27	12 of 27	54	NCT01592045	Trial comparisons
Arm I (Chemotherapy, Immunoglobulin Therapy) vs Arm II (Chemotherapy, Observation): serious adverse events	1 of 26	1 of 27	53	NCT00033293	Trial comparisons

1 to 10 of 40

See all 40 comparisons in its trials

Papers from its trials199

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32013055	RESULT	1	PubMed
31894292	RESULT	1	PubMed
31882719	RESULT	1	PubMed
31831767	RESULT	1	PubMed
31595663	RESULT	1	PubMed
31533931	RESULT	1	PubMed
31101621	RESULT	1	PubMed
30975030	RESULT	1	PubMed
30442501	RESULT	1	PubMed
30405781	RESULT	1	PubMed

1 to 10 of 199

See all 199 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005072

GET https://conductscience.org/api/diseases/v1/MONDO_0005072/drugs?page=2

API reference For AI assistants